

| SECTION | SUBJECT | PAGE |
|---------------------------|--|--------------------------|
| Antimicrobial Stewardship | Extended Use Antibiotics for Urinary Tract Infection | 1 of 3 |
| | Original | YY MM DD 15 06 26 |
| | Last Update | 17 12 04 |

Extended Use

With a few notable exceptions, antimicrobial therapy should be intended to treat an acute illness that should be resolved within a finite, limited time period¹. While re-infection and subsequent re-treatment may be expected to a certain extent, there are very few indications for true sustained use of antibiotics in the nursing home population. For the purposes of this discussion, this document will focus on antibiotics used for **prophylaxis and suppression** of urinary tract infections in the elderly.

Features of UTI in Nursing Homes

Based on the definition of a complicated UTI to be a UTI occurring in a patient with “a structural or functional abnormality of the genitourinary tract,” then it could be said that *most* UTIs in the nursing home are complicated (infections in males are always considered complicated)³.

Antibiotics for Prophylaxis

Prophylactic use of antimicrobials should be considered a last line option in most circumstances. Though there is evidence for prophylactic use of antibiotics in UTI in uncomplicated infections in adult females, there is currently no evidence to support this practice in geriatrics. A 2008 Cochrane review identified possible antibiotic options like nitrofurantoin, cotrimoxazole, cephalexin and quinolones as potential long-term treatments that are statistically shown to decrease incidence of UTIs. However, it should be noted that the subjects in these studies had very liberal inclusion criteria (e.g. non-pregnant females 14 years and older), but excluded subjects with renal failure. Furthermore, eradication of offending organisms is not possible; even in healthy individuals, upon cessation of the 6-12 month trial period, infections in the antibiotic prophylaxis groups returned to baseline².

| SECTION | SUBJECT | PAGE |
|---------------------------|--|--------------------------|
| Antimicrobial Stewardship | Extended Use Antibiotics for Urinary Tract Infection | 1 of 3 |
| | Original | YY MM DD 15 06 26 |
| | Last Update | 17 12 04 |

It is suggested that prophylactic use in the geriatric population will likely be unsuccessful due to re-infection with resistant organisms³. Whether the resistant organisms were already present at admission, or they are selected for due to frequent infections and treatments, one of the primary concerns about prophylaxis in the LTC population is the emergence of organisms resistant to all available treatments. In Calgary specifically, there is a noticeable difference in susceptibility to common UTI-causing pathogens as reported by Calgary Lab Services (CLS).

| | Ampicillin/ Amoxicillin | Cloxacillin | Amoxicillin/ Clavulanate | Pip/Tazo | Cephalexin (urine) | Cefazolin | Ceftriaxone | Ceftazidime | Clindamycin | Erythromycin | SXT | Norfloxacin (urine) | Ciprofloxacin | Nitrofurantoin (urine) | Fosfomycin (Urine) | Vancomycin | Gentamicin | Tobramycin | Tetracycline | | | | | | |
|-----------------------------|----------------------------|--------------|-----------------------------|--------------|-----------------------|--------------|-------------|--------------|-------------|--------------|-----------|------------------------|---------------|---------------------------|-----------------------|--------------|------------|--------------|--------------|----|----|----|----|----|----|
| | Community | Nursing Home | Community | Nursing Home | Community | Nursing Home | Community | Nursing Home | Community | Nursing Home | Community | Nursing Home | Community | Nursing Home | Community | Nursing Home | Community | Nursing Home | Community | | | | | | |
| Enterococcus faecalis | 100 | 100 | | | | | | | | | | | 87 | 70 | 99 | 99 | | | | | | | | | |
| Staphylococcus aureus (ALL) | | | 85 | 77 | | | | | 84 | 83 | 74 | 74 | 94 | 97 | | 68 | | | | 96 | 99 | | | | |
| •MSSA | | | 100 | 100 | | | | | 86 | 90 | 81 | 85 | 95 | 98 | | | | | | 96 | 98 | | | | |
| •MRSA | | | 0 | 0 | | | | | 74 | 60 | 32 | 32 | 88 | 97 | | | | | | 93 | 98 | | | | |
| Escherichia Coli (ALL) | 60 | 50 | | | 86 | 77 | 97 | 95 | 92 | 80 | | | | | | | | | | 92 | 85 | | | | |
| •ESBL | | | | | | | 94 | 90 | | | | | | 41 | 39 | 29 | 2 | 29 | 2 | 93 | 88 | | | | |
| Klebsiella oxytoca | | | | | 95 | 92 | 96 | 95 | 92 | 85 | | | | 96 | 95 | 98 | 98 | 98 | 98 | 91 | 90 | | | | |
| Klebsiella pneumoniae | | | | | 96 | 99 | 96 | 99 | 98 | 98 | | | | 94 | 93 | 98 | 97 | 98 | 96 | 43 | 48 | | | | |
| Proteus mirabilis | 76 | 65 | | | 98 | 99 | | | 97 | 97 | | | | 85 | 72 | 97 | 85 | 97 | 83 | | 94 | 95 | | | |
| Pseudomonas aeruginosa | | | | | 96 | 99 | | | | | | | | | | | | | | 83 | 95 | 94 | 93 | 97 | 99 |

All susceptibilities via antibiograms from Calgary Lab Services (<http://www.calgarylabservices.com/education-research/publications/microbiology-Antibiograms.aspx>)

*These organisms usually produce inducible B-lactamase which cause failure of 3rd generation B-lactam therapy, despite in vitro susceptibility indicated for treatment purposes.

Note: Please refer to the Calgary Lab Services website for the complete LTC antibiogram and others

As indicated by CLS data, there is significant variation in susceptibility amongst the same organisms in a nursing home setting. There is concern that overuse of currently effective antimicrobials may lead to the evolution of resistant mechanisms⁷.

Suppression

Antimicrobial “suppression” is a rare circumstance where an underlying infection is recognized but cannot be eradicated. In these cases, treatment should be limited to cases where

| SECTION | SUBJECT | PAGE |
|---------------------------|--|--------------------------|
| Antimicrobial Stewardship | Extended Use Antibiotics for Urinary Tract Infection | 1 of 3 |
| | Original | YY MM DD 15 06 26 |
| | Last Update | 17 12 04 |

symptomatic infection can be controlled only by sustained antibiotic therapy. Possible examples of this may include clients with ureteric stents, struvite stones, renal transplants, and in some cases, renal failure³. The dose and duration for this indication has not been proven by evidence and should be decided upon by the appropriate specialists (e.g. urology, infectious disease, nephrology, etc.) on an individualized basis.

References

- 1) LuttersM, Vogt-FerrierNB. Antibiotic duration for treating uncomplicated, symptomatic lower urinary tract infections in elderly women. *CochraneDatabase of Systematic Reviews* 2008, Issue 3. Art.No.:CD001535.DOI: 10.1002/14651858.CD001535.pub2.
- 2) Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C: Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. *Cochrane Database Syst Rev* 2004, , 3: CD001209.
- 3) Nicolle L; AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol.* 2005;16(6):349-360.
- 4) Calgary Lab Services 2016 Antibiograms. [Microbiology Antibiograms | Calgary Laboratory Services](#)
- 5) Nicolle LE. Urinary tract infection in geriatric and institutionalised patients. *Curr Opin Urol.* 2002;12:51–55.
- 6) Lichtenberger, P. Antimicrobial Prophylaxis in Women with Recurrent Urinary Tract Infections. *International Journal of Antimicrobial Agents* 38S (2011) 36– 41
- 7) Bergman et al.: Prevention of urinary tract infections in nursing homes: lack of evidence-based prescription? *BMC Geriatrics* 2011 11:69.
- 8) Kodner, CM. Recurrent Urinary Tract Infections in Women: Diagnosis and Management. *Am Fam Physician.* 2010;82(6):638-643.
- 9) Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM, Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society: Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis* 2005, 40:643-654.